Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis.
Tvorogov D, Thomas D, Liau NPD, Dottore M, Barry EF, Lathi M, Kan WL, Hercus TR, Stomski F, Hughes TP, Tergaonkar V, Parker MW, Ross DM, Majeti R, Babon JJ, Lopez AF. Tvorogov D, et al. Among authors: ross dm. Sci Adv. 2018 Nov 28;4(11):eaat3834. doi: 10.1126/sciadv.aat3834. eCollection 2018 Nov. Sci Adv. 2018. PMID: 30498775 Free PMC article.
Do we have to kill the last CML cell?
Ross DM, Hughes TP, Melo JV. Ross DM, et al. Leukemia. 2011 Feb;25(2):193-200. doi: 10.1038/leu.2010.197. Epub 2010 Sep 16. Leukemia. 2011. PMID: 20844563 Review.
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.
Branford S, Yeung DT, Ross DM, Prime JA, Field CR, Altamura HK, Yeoman AL, Georgievski J, Jamison BA, Phillis S, Sullivan B, Briggs NE, Hertzberg M, Seymour JF, Reynolds J, Hughes TP. Branford S, et al. Among authors: ross dm. Blood. 2013 May 9;121(19):3818-24. doi: 10.1182/blood-2012-10-462291. Epub 2013 Mar 20. Blood. 2013. PMID: 23515925 Free article.
202 results